Lb Pharmaceuticals Inc (LBRX)

Price$41.97Cached quoteAs of 2026-09-18 14:01 UTC

AI: Overvalued

Price checkThe valuation offers little protection if the lead drug’s pivotal trial disappoints.

Counting 28.7 million June shares, February’s 1.4 million near-free warrants, and July’s 4.3 million share-and-warrant issuance, the observed price implies roughly $1.53 billion of equity value. June cash and marketable securities plus July’s gross financing total about $478 million before fees and subsequent spending, leaving more than $1.0 billion attributed to an unapproved pipeline. With no revenue or earnings, that price requires meaningful odds of approval and commercial success. The positive midstage study helps, but the limited margin for failure supports an Overvalued verdict.

Big pictureThere are no sales or profits, so one clinical result drives most value.

LB Pharmaceuticals has no product revenue, and its 2025 net loss was $25.2 million. More importantly, spending accelerated as late-stage trials began: first-half 2026 operating cash use reached $60.9 million, versus $13.7 million a year earlier, while the second-quarter net loss was $51.6 million. Cash left after running and investing in the business is therefore negative, not durable. This is not a normally cyclical business tied to the economy; value moves mainly with trial data, regulator decisions, and funding needs.

Business strengthStrong funding and encouraging midstage data help, but lasting drug benefits remain unproved.

At June-end, the company reported $327.8 million of cash, cash equivalents, and marketable securities against only $5.2 million of debt; July added $150 million gross. Management expects funding beyond the second quarter of 2029. In the 359-patient NOVA-1 study, every tested dose beat placebo, with symptom-score advantages of 4.7 to 6.8 points. However, treatment lasted only four weeks; average weight gain was 3.5 to 4.6 kilograms versus 2.1 for placebo, and higher prolactin appeared. The balance sheet is strong, but the product evidence is not yet durable.

What could change the storyPivotal success could justify the premium, while failure would expose heavy downside.

The roughly 460-patient NOVA-2 pivotal trial, meaning a study intended to support approval, is the clearest test. Strong symptom improvement with acceptable weight, movement, and prolactin effects could validate the roughly $1.0 billion pipeline value and support a regulatory meeting in late 2027; a miss would leave mainly cash and earlier-stage mood-disorder trials. Capital allocation is aggressive: two 2026 private placements sold shares and near-free warrant rights equivalent to about 9.0 million shares, roughly 36% of year-end 2025 shares. There are no dividends or buybacks to offset dilution.

AI: News

Pivotal Results AcceleratedFaster enrollment brought the crucial schizophrenia trial result forward, shortening the wait for decisive evidence.

On July 22, management moved expected main results for NOVA-2 from the second half to the first half of 2027 because enrollment was faster than projected. The randomized, placebo-controlled study plans about 460 patients across 25 U.S. sites. Shares rose 10.9% that day on higher volume; the timing makes the announcement a plausible contributor, but does not prove causation. Earlier evidence reduces waiting risk, although the trial’s outcome remains fully uncertain.

New Institutional FinancingFresh institutional funding lengthened the runway while adding meaningful dilution for existing owners.

On July 29, the company agreed to raise $150 million gross by selling 3.58 million common shares and near-free warrants for another 0.72 million. That is potential dilution of about 15% relative to June’s basic share count, but it funds new LB-102 uses and extends operating runway beyond the second quarter of 2029. Shares rose 11.6% that day; the financing may have signaled institutional support, though price timing alone cannot establish why the stock moved.

Trial Spending SurgedCash remained ample, but trial expansion drove a steep increase in research spending and losses.

On August 11, the company reported $327.8 million in cash and marketable securities at June-end, before July’s financing. Second-quarter research spending rose to $44.1 million from $2.4 million a year earlier, and the quarterly net loss reached $51.6 million. Management still projected funding beyond the second quarter of 2029. The update matters because the balance sheet can carry several trials, but the sharp spending increase shows how quickly that cushion can shrink as development broadens.

Loading local price history

Revenue

2022

2023

2024

2025

Net income

2022

2023

2024

2025

Free cash flow

2023

2024

2025

Total cash / debt

CashTotal debt

2022

2023

2024

2025

Financial statements

	2025	2024	2023	2022
Revenue	$0	$0	$0	$0
Research & development	$16.7M	$51.2M	$7.8M	$1.3M
Operating expenses	$30.4M	$64.8M	$11.4M	$2.8M
Operating income	−$30.4M	−$64.8M	−$11.4M	−$2.8M
EBITDA	−$30.1M	−$64.7M	−$1.4M	−$12.2M
Net income	−$25.2M	−$63.1M	−$6.3M	−$14.3M
Basic EPSper basic share	-$0.00	-$0.18	-$1.77	-$4.05
Diluted EPSper diluted share	-$0.00	-$0.18	-$1.77	-$4.05

Review official source filings ↗

Owners

Reported shareholders

Reference date Jun 30, 2026

11.69%of listed shares

Deep Track Capital, LP3.35M shares · Jun 30, 2026

View holders

Top 20 reported holders of LBRX
Holder	% owned
Deep Track Capital, LP	11.69%3.35M shares
BlackRock, Inc.	9.53%2.73M shares
RA CAPITAL MANAGEMENT, L.P.	7.70%2.21M shares
Nantahala Capital Management, LLC	7.34%2.11M shares
Nussbaum Ran	≈6.36%1.82M shares
Pontifax Management 4 G.P. (2015) Ltd.	≈6.36%1.82M shares
Trails Edge Capital Partners, LP	5.31%1.52M shares
Commodore Capital LP	5.23%1.5M shares
JPMORGAN CHASE & CO	5.22%1.5M shares
TCG Crossover Management, LLC	5.05%1.45M shares
Caligan Partners LP	5.01%1.44M shares
Spruce Street Capital LP	4.80%1.38M shares
VANGUARD CAPITAL MANAGEMENT LLC	3.39%971.17K shares
Balyasny Asset Management L.P.	3.21%921.47K shares
Vida Ventures GP III, L.L.C. / Belldegrun Arie / Vida Ventures III, L.P. / Vida Ventures Management Co. LLC / Vida Ventures III-A, L.P.	≈3.08%883.68K shares
Alyeska Investment Group, L.P.	3.01%863.95K shares
Vivo Capital, LLC	2.79%800K shares
Deep Track Special Opportunities Fund, LP	≈2.32%666.67K shares
Nan Fung Group Holdings Ltd	2.20%630.66K shares
GEODE CAPITAL MANAGEMENT, LLC	2.14%612.79K shares

Percentages use 28.68M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.

Reported positions exceed 100% in total, so the circle shows the selected holder only.

Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data

Insider buys & sells

Jul 1, 2024–Jun 30, 2026

Buys8$85.00M disclosed value

Sells (SEC code S)0$0.00 disclosed value

Transaction	Insider	Type	Shares	Price	Value	Owned after
Feb 6, 2026Form 4	KROIN DAVID +3TenPercentOwner	BuyPre-Funded Warrants (Right to Buy) · derivative · indirect	93.9K	$21.17	$1.99M	93.9K
Feb 6, 2026Form 4	KROIN DAVID +3TenPercentOwner	BuyPre-Funded Warrants (Right to Buy) · derivative	378.4K	$21.17	$8.01M	378.4K
Sep 12, 2025Form 4	Deep Track Capital, LP +2TenPercentOwner	BuyCommon Stock · indirect	666.7K	$15.00	$10.00M	666.7K
Sep 12, 2025Form 4	Deep Track Capital, LP +2TenPercentOwner	BuyCommon Stock	2.00M	$15.00	$30.00M	2.69M
Sep 12, 2025Form 4	Pontifax Management 4 G.P. (2015) Ltd.TenPercentOwner	BuyCommon Stock · indirect	1.00M	$15.00	$15.00M	1.41M

Review ownership filings at SEC.gov ↗

Community posts

View community

It’s quiet here.

No posts about LBRX yet. Start the conversation.

Write the first post

Lb Pharmaceuticals Inc (LBRX)

Financial charts

Financial statements

Owners

Insider buys & sells

Community posts

It’s quiet here.